<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01580696</url>
  </required_header>
  <id_info>
    <org_study_id>05-20025/20288</org_study_id>
    <nct_id>NCT01580696</nct_id>
  </id_info>
  <brief_title>Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer</brief_title>
  <official_title>Phase I/IIa Trial of Folate Binding Protein (FBP) Peptide (E39) Vaccine in Ovarian and Endometrial Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>COL George Peoples, MD, FACS</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>San Antonio Military Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Folate binding protein (FBP) is highly over-expressed in breast, ovarian and endometrial
      cancers and is the source of immunogenic peptides (E39) that can stimulate cytotoxic T
      lymphocytes (CTL) to recognize and destroy FBP-expressing cancer cells in the laboratory. The
      purpose of this study is to test whether a peptide-based vaccine consisting of the E39
      peptide mixed with the FDA-approved immunoadjuvant granulocyte macrophage colony-stimulating
      factor (GM-CSF) is safe and effective at inducing an in vivo peptide-specific immune
      response. Furthermore, the investigators intend to determine the best dose of the vaccine to
      utilize to produce this immunity most efficiently. The investigators will determine whether
      immunity to FBP will prevent clinical recurrence. Additionally, the investigators will
      compare these results with results from a trial utilizing the E75 peptide (from the HER2/neu
      protein) in ovarian and endometrial cancer patients in preparation for studying a combination
      vaccine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, investigators intend to assess the safety and document local and systemic
      toxicity to the folate binding protein (FBP) peptide vaccine E39 + GM-CSF given in the
      adjuvant setting. Investigators also intend to determine the maximum tolerated dose (MTD) and
      optimal biologic dose (OBD) for the peptide vaccine, as well as evaluate the in vivo cellular
      immune response to the vaccine. Time to recurrence in the vaccinated patients vs. matched
      controls will be tracked.

      The primary endpoints are the safety and optimal dosing of the vaccine to induce an in vivo
      peptide-specific immune response. The clinical endpoint is time to recurrence from date of
      enrollment.

      The study will be a multicenter, phase I/IIa trial of the FBP peptide E39 + GM-CSF. The
      target study population is female civilian and military health care beneficiaries over the
      age of 18 years with a diagnosis of ovarian, endometrial, fallopian, or peritoneal cancer who
      have undergone primary surgical and medical therapies, are post-menopausal or have surgically
      induced menopause, and are currently without evidence of disease. Disease-free subjects after
      standard of care multi-modality therapy will be screened and HLA typed since the E39 vaccine
      is specific for HLA-A2+ patients (approximately 40% of the US population). HLA-A2-patients
      will be followed as prospective clinically matched controls for recurrence.

      HLA-A2+ patients who meet all other eligibility criteria will be tested for biomarkers that
      indicate progression/recurrence of ovarian and advanced uterine cancer FBP. FBP+ and HLA-A2+
      patients will be vaccinated with the FBP peptide (E39) and GM-CSF. HLA-A2-negative patients
      and those individuals who are eligible to receive the vaccine but who decline will be
      followed clinically as matched controls for disease recurrence/progression.

      Treatment will begin within one month of the subject enrollment in the study and confirmation
      of eligibility. The 1 ml by volume vaccine will be administered intradermally in 0.5 mL
      inoculums at two different sites within 5 cm of each other. A total of six vaccinations will
      be given every 3-4 weeks and will be administered in the same lymph node draining area. The
      dose escalation scheme is for three patients to receive each of the doses: 100, 500, and
      1,000 mcg of peptide. Patients will be enrolled consecutively. An additional three patients
      may receive a given a dose depending on the presence of dose limiting toxicity (DLT). Prior
      to the fourth vaccination, each patient will be assessed for liver, renal, and hematopoietic
      function. If organ function is stable and no DLT is seen, then the patient will continue with
      the series. After the last patient in a given dose group has completed the third inoculation
      and organ function is proven stable, then the next dose group will be initiated. Optimal
      biologic dose (OBD) is defined as the minimum dose of the vaccine that gives the most optimal
      and lasting in vivo immunologic response to the vaccinated peptide. Up to 15 patients will be
      vaccinated at the OBD.

      Additionally, the E39-vaccinated patients will be randomized to receive either E39 or J65 (an
      attenuated version of E39) as a booster to promote long-term E39-specific immunity. The
      clinical endpoints are long-term FBP immunity, time to recurrence from date of enrollment and
      5-year survival rate. Those individuals who are eligible to receive the vaccine, but who
      decline and all HLA-A2- patients will be followed clinically as matched controls for disease
      recurrence/progression

      Subjects will be followed for safety issues, immunologic response and clinical recurrence.
      Subjects will be monitored 48-72 hours after each inoculation for reaction to the inoculation
      as well as documentation of any adverse effects experienced. Immunologic response will be
      documented with both ex vivo phenotypic and functional assays as well as in vivo delayed type
      hypersensitivity (DTH) reactions. All patients will be followed for a total of 5 years to
      document disease-free status.

      The investigators intend to enroll up to 60 patients will be enrolled study-wide (15-24 in
      the vaccine arm, up to 36 in the control arm). With accrual beginning in April 2012
      enrollment of the last patient is anticipated to occur in December 2014 followed by a
      five-year follow-up period. The duration of the trial is expected to be seven years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">July 31, 2016</completion_date>
  <primary_completion_date type="Actual">July 31, 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>3+3 dose escalation study of E39 + GM-CSF in HLA-A2+ patients with HLA-A2- patients followed as a control arm</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Local/Systemic Toxicity</measure>
    <time_frame>Duration of the vaccine series</time_frame>
    <description>Standard local and systemic toxicities will be collected and graded per the National Cancer Institute Common Terminology Criteria for Adverse Events, v4.03 toxicity scale. For the vaccine series (one vaccine/month for six months), patients will be monitored closely for one hour after vaccine inoculation with questioning, serial exams and vital signs every 15 minutes to observe for a hypersensitivity reaction. Patients will also return to the clinic 48-72 hours after each inoculation for questioning regarding systemic toxicity and to examine and measure inoculation site local reactions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>Disease-free survival up to 36 months</time_frame>
    <description>Disease-free survival (DFS) for all patients regardless of randomization will be determined by the patients' own physicians at the individual study sites during routine follow-up screening. This will occur every three months for the first 24 months after diagnosis and then every six months for an additional 36 months.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Endometrial Cancer</condition>
  <condition>Fallopian Cancer</condition>
  <condition>Peritoneal Cancer</condition>
  <arm_group>
    <arm_group_label>Non-vaccine clinically matched control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HLA-A2-negative patients and HLA-A2+ patients who decline the vaccine will be followed clinically as matched controls for disease recurrence/progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E39 peptide (100mg)/GM-CSF vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HLA-A2+ patients receive 100mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of either E39 or E39' (J65) 6 and 12 months after completion of the primary vaccine series.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E39 peptide (500mg) /GM-CSF vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HLA-A2+ patients receive 500mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of either E39 or E39' (J65) 6 and 12 months after completion of the primary vaccine series.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E39 peptide (1000mg) /GM-CSF vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HLA-A2+ patients receive 1000mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of either E39 or E39' (J65) 6 and 12 months after completion of the primary vaccine series.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>E39 peptide (100mg)/GM-CSF vaccine</intervention_name>
    <description>100mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose</description>
    <arm_group_label>E39 peptide (100mg)/GM-CSF vaccine</arm_group_label>
    <other_name>E39 peptide (FBP, 191-199, EIWTHSTKV)</other_name>
    <other_name>GM-CSF (sargramostim)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-vaccine clinically matched control group</intervention_name>
    <description>HLA-A2-negative patients or HLA-A2-positive patients who decline the vaccine will be followed clinically as matched controls for disease recurrence/progression. No experimental treatment will be administered to this group.</description>
    <arm_group_label>Non-vaccine clinically matched control group</arm_group_label>
    <other_name>Clinical tracking for disease progression/recurrence</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>E39 peptide (500mg)/GM-CSF vaccine</intervention_name>
    <description>500mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose</description>
    <arm_group_label>E39 peptide (500mg) /GM-CSF vaccine</arm_group_label>
    <other_name>E39 peptide (FBP, 191-199, EIWTHSTKV)</other_name>
    <other_name>GM-CSF (sargramostim)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>E39 peptide (1000mg)/GM-CSF vaccine</intervention_name>
    <description>1000mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose</description>
    <arm_group_label>E39 peptide (1000mg) /GM-CSF vaccine</arm_group_label>
    <other_name>E39 peptide (FBP, 191-199, EIWTHSTKV)</other_name>
    <other_name>GM-CSF (sargramostim)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients will be included in the study based on the following criteria. (Enrollment may
        commence 1 month from completion of standard primary therapies and up to two years after
        completion of treatment.)

          1. Ovarian or endometrial, fallopian and peritoneal cancer

          2. Completion of primary first-line therapies (i.e., surgery, chemotherapy, immunotherapy
             and radiation therapy as appropriate per standard of care for patient's specific
             cancer)

          3. Stage I-IV but no evidence of disease (NED) after completion of primary therapies

          4. Post-menopausal or rendered surgically infertile

          5. HLA-A2+ patients will receive the vaccine; HLA-A2- patients will be eligible to
             participate in the control group

          6. Good performance status (Karnofsky &gt; 60%, ECOG â‰¤ 2)

          7. CBC, CMP, and CA-125 within 2 months of enrollment

          8. Capable of informed consent

        Exclusion Criteria:

        Patients will be excluded from the study based on the following criteria:

          1. Receiving immunosuppressive therapy to include chemotherapy, steroids, or methotrexate

          2. Not post-menopausal or not rendered surgically infertile

          3. Pregnancy

          4. In poor health (Karnofsky &lt; 60%, ECOG &gt; 2)

          5. Tbili &gt; 1.5, creatinine &gt; 2, hemoglobin &lt; 10, platelets &lt; 50,000, WBC &lt; 2,000

          6. Active interstitial lung disease; asthma requiring more than as needed bronchodilators
             for management; or other autoimmune lung disease

          7. Involved in other experimental protocols (except with permission of the other study PI
             and completion of the other study dosing regimen)

          8. History of autoimmune disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John C Elkas, MD, JD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mid-Atlantic Gynecologic Oncology &amp; Pelvic Surgical Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>COL George E. Peoples, MD</last_name>
    <role>Study Director</role>
    <affiliation>Brooke Army Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mid-Atlantic Gynecologic Oncology &amp; Pelvic Surgery Associates</name>
      <address>
        <city>Annandale</city>
        <state>Virginia</state>
        <zip>22003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2012</study_first_submitted>
  <study_first_submitted_qc>April 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2012</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>San Antonio Military Medical Center</investigator_affiliation>
    <investigator_full_name>COL George Peoples, MD, FACS</investigator_full_name>
    <investigator_title>Chief, Surgical Oncology, Brooke Army Medical Center, Director and Principal Investigator, Cancer Vaccine Development Program</investigator_title>
  </responsible_party>
  <keyword>Folate binding protein</keyword>
  <keyword>E39 vaccine</keyword>
  <keyword>Stage I-IV ovarian cancer</keyword>
  <keyword>Stage I-IV endometrial cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

